Osteoporosis – Landscape & Forecast – Disease Landscape & Forecast

The osteoporosis therapy market will experience rapid growth over the forecast period owing to the increasing prevalence of postmenopausal osteoporosis disease and the increasing uptake of Evenity and Tymlos. This growth will be offset to a certain extent by the generic erosion of existing brands. The relatively low diagnosis and drug treatment rates for osteoporosis, owing to the asymptomatic nature of the disease, will also continue to rein in the market. Other constraints impacting treatment rates include safety concerns associated with bisphosphonates, particularly osteonecrosis of the jaw and atypical femoral fractures, and the strict reimbursement policies limiting the use of effective anabolic therapies in low-risk patients. Driven largely by their widespread generic availability and strong physician familiarity, bisphosphonates continue to dominate first-line treatment, creating a significant barrier to the uptake of novel therapies. Emerging therapies will need to demonstrate a favorable clinical risk-benefit balance, at a competitive price, to challenge the bisphosphonates as first-line treatments.


  • What are the drivers and constraints in the osteoporosis market, and how will the market evolve over the forecast period?
  • How has Amgen / UCB’s Evenity been integrated into the treatment algorithm in the United States, the United Kingdom, Germany, Italy, Spain, and Japan, and how will it be positioned in France?
  • What do thought leaders think of the emerging therapies for osteoporosis and the current treatments and practices? How will uptake of the emerging agents impact current market-leading therapies?
  • What impact will the generic entries of key brands, such as Prolia, have on the osteoporosis market?


Geography: United States, EU5, Japan.

Primary research: 18 country-specific interviews with thought-leading rheumatologists and endocrinologists. Supported by survey data collected for this and other Clarivate research.

Epidemiology: Prevalence of osteoporosis by country, with diagnosed and drug-treated population.

Features: 10-year, annualized, drug-level sales and patient share of key osteoporosis therapies through 2032, segmented by brands / generics.

Emerging therapies: Phase 2/3/PR: 1 drug; coverage of select early-phase products.


Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents